(Q34569082)

3 August 2017

1 reference

title

Efficacy of highly active antiretroviral therapy in HIV-1 infected children (English)

1 reference

3 August 2017

anti-retroviral agent

0 references

author name string

Annemarie M C van Rossum

series ordinal

1

1 reference

PubMed ID

11901656

3 August 2017

Pieter L A Fraaij

series ordinal

2

1 reference

PubMed ID

11901656

3 August 2017

Ronald de Groot

series ordinal

3

1 reference

3 August 2017

1 February 2002

1 reference

Lancet Infectious Diseases

3 August 2017

1 reference

3 August 2017

2

1 reference

3 August 2017

93-102

1 reference

3 August 2017

2

1 reference

Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Protease inhibitor therapy in children with perinatally acquired HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

A one year experience: T cell responses and viral replication in children with advanced human immunodeficiency virus type 1 disease treated with combination therapy including ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Combination antiretroviral therapy including ritonavir in children infected with human immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Immunologic and virologic responses to HAART in severely immunocompromised HIV-1-infected children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

HIV-1 dynamics in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Early prognostic indicators in primary perinatal human immunodeficiency virus type 1 infection: importance of viral RNA and the timing of transmission on long-term outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

A phase I/II study of the protease inhibitor indinavir in children with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Pharmacokinetics of indinavir and low-dose ritonavir in children with HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Combination Nucleoside Analog Reverse Transcriptase Inhibitor(s) Plus Nevirapine, Nelfinavir, or Ritonavir in Stable Antiretroviral Therapy-Experienced HIV-Infected Children: Week 24 Results of a Randomized Controlled Trial - PACTG 377

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Nelfinavir pharmacokinetics in HIV-infected children: a comparison of twice daily and three times daily dosing

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Comparison of ritonavir plus saquinavir- and nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency type 1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Effectiveness of antiretroviral therapy initiated before the age of 2 months in infants vertically infected with human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Viral measurement by polymerase chain reaction-based assays in human immunodeficiency virus-infected infants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Tolerance of efavirenz in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Development and significance of zidovudine resistance in children infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Early effects of antiretroviral combination therapy on activation, apoptosis and regeneration of T cells in HIV-1-infected children and adolescents.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Early recovery of CD4+ T lymphocytes in children on highly active antiretroviral therapy. Dutch study group for children with HIV infections.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Immune repopulation after HAART in previously untreated HIV-1-infected children. Paediatric European Network for Treatment of AIDS (PENTA) Steering Committee.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Thymus volume correlates with the progression of vertical HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Effect of HIV on thymic function before and after antiretroviral therapy in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

HIV-associated lipodystrophy syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ -lymphocyte count and CD4+ -lymphocyte percentage at baseline and use of protease inhibitors and stavudine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2802%2900183-4

7 January 2021

10.1016/S1473-3099(02)00183-4

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

11901656